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Identiﬁcation of biomarkers of Alzheimer’s Disease (AD) is a critical priority to eﬃciently diagnose the patients, to stage the
progression of neurodegeneration in living subjects, and to assess the eﬀects of disease-modiﬁer treatments. This paper addresses
the development and usefulness of preclinical neuroimaging biomarkers of AD. It is today possible to image in vivo the brain of
small rodents at high resolution and to detect the occurrence of macroscopic/microscopic lesions in these species, as well as of
functional alterations reminiscent of AD pathology. We will outline three diﬀerent types of imaging biomarkers that can be used
in AD mouse models: biomarkers with clear translational potential, biomarkers that can serve as in vivo readouts (in particular in
the context of drug discovery) exclusively for preclinical research, and ﬁnally biomarkers that constitute new tools for fundamental
research on AD physiopathogeny.
1.Introduction
For more than a century, the primary criteria to diagnose
Alzheimer’s disease (AD) have been relying on clinical
observations (development of progressive dementia with a
rapid onset of episodic memory impairments). Thanks to
the modern reﬁnements of neuropsychological evaluation it
is now possible to identify prodromal AD in patients with
mild cognitive impairment (MCI) with a speciﬁcity of 90%
[1]. However, the postmortem examination of brain tissues
revealing the pathognomonic lesions of AD (neuroﬁbrillary
tangles and senile plaques) is currently the only way to
perform a deﬁnite diagnosis of this neurodegenerative dis-
ease [2]. In vivo biomarkers are gaining ground in bridging
the gap between clinical and neuropathological diagnosis
of AD. The validation of new AD biomarkers has become
a priority to allow an early diagnosis but also to better
describe the natural history of the disease [3]a n dk e y
physiopathological events associated with it [4]. In addition,
it is crucial to identify surrogate markers allowing the
evaluation of treatment eﬀects and the dissociation between
purely symptomatic treatments and disease-modiﬁer actions
of the therapies. Today, the most widely used AD markers
are based on magnetic resonance imaging (MRI), positron
emissiontomography(PET),andbiochemicalexamsofbody
ﬂuids.
The evaluation of brain atrophy markers by structural
MRI is the main approach to complement neuropsycholog-
ical assessment. In particular, medial temporal lobe atrophy
is considered to be an excellent criterion for the diagnosis
of AD [5]. Volumetric analysis of brain tissues allows to
predict conversion from MCI to incipient AD, to dissociate
morphological anomalies between patients with early-onset
versus late-onset forms of the disease [6, 7]a n de v e nt o
classify the various clinical subtypes of MCI [8]. Cortical
hypometabolism quantiﬁed by functional MRI (fMRI) or
PET is also constantly reported in AD patients, especially
in the parietal-temporal regions [9, 10]. It is, however,2 International Journal of Alzheimer’s Disease
undoubtedly the direct imaging of AD brain lesions with
PET radioligands [11] that has attracted the most successful
research opportunities these last years. Various ligands
derived from Congo red, thioﬂavin T, or other molecules
showing aﬃnity for aggregated Aβ have been engineered
[12, 13]. The use of the PiB (Pittsburgh compound B)
ligand described in the original work of Klunk and Engler
[14] has received particular attention and has been validated
through multicentric studies. This ligand allows the in vivo
detection and quantiﬁcation of brain amyloidosis. PiB has
been used to follow the evolution of amyloidosis during
disease progression, and to study its relationship with
cognitive decline and with disease-modiﬁer treatments [15,
16].Despiteitsadvantages,PiBpresentsseverallimitations:it
can display high retention in the brain of aged nondemented
subjects [17]; it does not readily detect soluble oligomeric
Aβ conformations considered to be highly pathogenic [18];
it shows high aﬃnity for vascular amyloid deposits that may
vary from one patient to the other and can be observed
in non-AD conditions [19, 20]. In humans, amyloid load,
but also tau pathology, can concurrently be evaluated from
peripheralmarkers,forinstance,bymeansofproteindosages
in cerebrospinal ﬂuids (CSFs). The combination of various
CSF markers (e.g., Aβ 42/Aβ 40 ratio [21], Aβ/tau ratio [22],
or tau/phospho-tau ratio [23]) furthermore increases the
sensitivity and speciﬁcity for AD diagnosis. Recent studies
even suggest that amyloid load as detected by PiB-PET
and Aβ concentrations measured in the CSF are inter-
correlated [24, 25]. CSF dosages can thus be more cost-
eﬃcient alternatives to PET examination for the evaluation
of amyloid load in patients.
Because of the multiple biomarkers available for the
followup of AD brain pathology, recent consensus eﬀorts
have led to the conclusion that the diagnosis of AD should
ﬁrst rely on the evaluation of a core clinical criterion
(gradual impairment of episodic memory) then on con-
current supportive features, including sets of biological
markers (brain atrophy, CSF and plasmatic dosages, cortical
hypometabolism, PiB retention, etc.) [26].
Preclinical research, mainly based on the use of mouse
models of AD, is an emerging ﬁeld in the area of biomarkers
discovery and validation. Considering the studies performed
inhumans,theidentiﬁcationandvalidationofbiomarkersin
cohorts of patients ironically suﬀer from the lack of deﬁnite
diagnosis of AD in the studied subjects. The vast majority of
biomarker studies hence rely on the analysis of cognitively
normal subjects compared with patients presenting a (high)
suspicion of AD dementia. However, some of the controls
included in the studied cohorts might present with a
preclinical form of AD and display initial neuropathological
alterations, albeit not declaring overt detectable cognitive
symptoms. Also, the deﬁnite neuropathological conﬁrma-
tion of early AD diagnosis in the patients is nearly impossible
to obtain in these populations (see however [27]). On
the contrary, animal models are speciﬁcally engineered to
homogeneously reproduce AD brain lesions. This allows to
circumvent biases and limitations encountered in human
studies that obviously slow down the discovery and valida-
tion of new biomarkers of the disease.
Here we will review the most widely used AD biomarkers
and their associated techniques that can be studied or
deployed in animal models (see Figure 1). We will focus on
morphological and microscopic biomarkers of AD as well
as on functional markers. The relevance/importance of the
preclinicalstudiesonADbiomarkerswillbediscussed.Many
rationalizations will be explored in parallel throughout this
paper.
(1) First, the discovery of new biomarkers in AD animal
models can be implemented with a translational aim
with the hope that it will ultimately pave new ways
for practical applications in human patients. Indeed,
we still need to reﬁne the existing markers of AD and
concurrently identify new biomarkers.
(2) In parallel, in vivo neuroimaging of biomarkers
in AD animal models can provide crucial infor-
mation to better understand the disease processes.
For instance, the analysis of AD models might
helpdisentanglingthetemporalrelationshipbetween
the neuropathological lesions themselves and deci-
phering their impact on neuromorphology and on
brain function. Advances in our knowledge of AD
physiopathogenyhave hencebeenassociatedwiththe
development of new preclinical imaging techniques
applied to AD transgenic mice, such as in vivo two-
photon laser scanning microscopy [28].
(3) Finally, preclinical biomarkers can also be used to
follow up animal models during drug evaluation.
2. Imagingof Brain Anatomy in
ADMouseModels
In humans, brain atrophy is one of the best-established
markers for the diagnosis and prognosis of AD. Detecting
and quantifying the process of atrophy in the rodent brain
might be viewed as a challenge as the mouse brain is
approximately 3000-fold smaller than the human cerebrum.
Theuseofhigh-ﬁeldMRIhasneverthelessallowedbypassing
thesetechnicallimits.Invivoanalysisofbrainmorphologyin
preclinical models allows to longitudinally monitor the pos-
sible onset and progression of localized atrophies [29]a n d
also to visualize the eﬀects of disease-modiﬁer treatments
[30].
The preclinical study of brain atrophy in AD animal
modelshasbeenmainlyperformedintransgenicmouselines
carrying familial AD mutations (APP and/or PS1-2 genes)
and developing brain amyloidosis. The ﬁrst reports were
obtained in the PDAPP model and demonstrated that these
transgenic mice overexpressing mutant APP display a severe
atrophy of the medial temporal lobe with a focus on the
hippocampus [31–36]. These original observations, derived
from in vivo experiments and/or from postmortem analysis,
suggested a similarity between morphological anomalies in
AD patients and in mouse models; however, other data
strongly argue against this initial statement.
(1) Brain atrophy as described in AD transgenic lines,
havemultiplefociandcaninvolvebrainareasthatareInternational Journal of Alzheimer’s Disease 3
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Figure 1: Summary of imaging techniques. This ﬁgure schematizes the principal methodologies and tools that can be used to image in vivo
the brain lesions and functional alterations developed by mouse models of AD. Radioligands analyzed by PET (green dots) can be used to
map brain metabolic deﬁcits in APP(xPS1) transgenic mice. Their relevance for plaque detection in mouse models is more controversial.
ApplicationsderivedfromsmallanimalMR-basedimagingtechniques(reddots)aremoreversatile.MRIallowsthedetectionofpathological
markers at the regional level (e.g., evaluation of brain atrophy) and also at a microscopic resolution (e.g., visualization of amyloid plaques).
In vivo MRI is also a tool to assess functional markers of the pathology such as anomalies in brain perfusion. The recent development of
manganese-enhanced MRI has opened new opportunities to map in vivo brain connectivity and neuronal activity with an exquisite spatial
resolution. The detection of discrete markers at the (sub)cellular level relies today on the use of high resolution, but also more invasive,
imaging techniques that require direct access to brain tissues through a craniotomy in anaesthetized animals: with multiphoton microscopy
(blue dots) it is for instance possible to detect intraneuronal neuroﬁbrillary tangles as well as dystrophic neurites in APP(xPS1) transgenic
mice.
not usually atrophied in AD patients. For instance,
posterior subcortical atrophy (mesencephalon) is
displayed in APPxPS1 transgenic mice [37]. Also,
white matter anomalies (including ﬁber tract atrophy
in diﬀerent regions: corpus callosum, anterior com-
missure, dorsal hippocampal commissure, fornix,
corticospinal tract, etc.) have been described in
various AD transgenic lines [37–39]. These neu-
ropathological alterations encountered in AD mouse
models, especially those aﬀecting callosal ﬁbers [33]
are hardly evocative of human pathology, both in
qualitative and in quantitative aspects.
(2) Moreover, in some mouse lines, the hippocampal
atrophy of AD transgenics appears to have a very
early onset during ontogenesis, which contrasts with
the slow and gradual atrophy process depicted in AD
patients.ThedataobtainedinAPP(xPS1)micemight
thus underpin the occurrence of developmental
abnormalities rather than of the true age-dependent
AD-like brain atrophy [35]. Furthermore, the atro-
phy of the hippocampus is not constantly reported
in AD transgenics. In a particular severely aﬀected
APPxPS1 model we demonstrated that there was no
signiﬁcant volume reduction of this brain area, even
in the oldest animals [37]. In this study, the lack
of hippocampal atrophy was further conﬁrmed by
postmortemhistologicalassessment.Inaddition,two
recent MRI studies performed on other APPxPS1
transgenic mice depicted a paradoxical accelerated
growth of the hippocampus in the transgenics as
compared to the wild-type animals [39, 40].
These puzzling data have to be reinterpreted in the
context of the amyloid cascade hypothesis. The major tenet
of this physiopathological hypothesis is that the deposition
of Aβ in brain parenchyma precedes and triggers subsequent4 International Journal of Alzheimer’s Disease
brain anomalies including tissue loss and atrophy. Obser-
vations in APP(xPS1) transgenic mice somewhat dispute
this belief: atrophy can be observed before the onset of
brain amyloidosis or can concurrently be absent despite a
heavy local amyloid burden. In addition, no correlations
between amyloid load and overall brain volumes have been
highlighted [37].
Brain volumetry, even when assessed in vivo, is thus a
questionable biomarker in AD APP(xPS1) transgenic mice.
Therefore, one has to be cautious when using brain volumes
as morphological readouts for preclinical research as it has
become clear that brain tissue atrophies are qualitatively
and quantitatively diﬀerent in mouse models of brain
amyloidosis and in AD patients. This obviously constitutes
a pitfall for subsequent translational eﬀorts.
3.Imagingof Brain Microscopic Lesions in
ADMouseModels
3.1. Indirect Detection of Cerebral Amyloidosis. APP(xPS1)
mouse lines are an adequate model to develop new imaging
techniques in order to follow up onset and progression
of amyloid burden. As a ﬁrst step, global MR parameters
expected to reﬂect Aβ deposition have been explored. For
example, a reduction in T2 relaxation time has been depicted
in APPxPS1 mouse lines [41, 42]. Such reduction in T2
is presumably explained by Aβ accumulation as stresses
the correlation between T2 and histologically-assessed local
amyloid load [43]. There is, however, an old controversy
whethersimilarabnormalrelaxationtimescanbedepictedin
humanADbrainsornot(see[44]but [45, 46]),whichsheds
some doubts on the possibility to extrapolate preclinical
ﬁndings to the development of new valid diagnostic tools for
human patients.
3.2. Direct Imaging of Plaques
(and of Other Microscopic Lesions)
3.2.1.InVivoMultiphotonMicroscopyImaging. Intransgenic
mice, in vivo multiphoton microscopy is a brain imaging
modality that allows to image amyloid deposits and associ-
ated lesions in small tissue volumes at very high resolution
(1μm) (for reviews of the methods, see [28, 47]). After
surgery involving local craniotomy [48]aﬂ u o r e s c e n td y e
(e.g., thioﬂavin S or methoxy-X04) can be administered
peripherally to label plaques and visualize them through the
skull open window, using nondestructive multiphoton laser
excitation. The ﬁeld of view of the technique is limited, but
images can be eﬃciently acquired from cortical surface up
to 800μm of depth. Visualization of vascular arborizations
(intravenous injection of a ﬂuorescent dye such as Texas red
dextran) is generally performed simultaneously to provide
constant landmarks for repeated imaging. Multiphoton
imaging methods have also been successfully applied to
visualize neuroﬁbrillary lesions in vivo. For example, Spires-
Jones and coworkers labeled in vivo the NFTs of rTg4510
mice, a model of taupathy, by application of thioﬂavin S on
brain surface after dura resection [49, 50].
In vivo multiphoton microscopy has signiﬁcantly
increased our knowledge on AD physiopathogeny. Indeed,
the method allows in vivo longitudinal studies (across
weeks or months) of the kinetics of plaque progression
[51, 52] and measurements of the eﬀects of treatments (e.g.,
immunotherapies) on plaque clearance [53]. Using these
methods, Meyer-Luehmann and colleagues [54]s u g g e s t e d
that the initial formation of plaques might be an acute event
(plaques were observed to form quickly within 24 hours).
However, these observations have recently been challenged
byanotherreportindicatingthatamyloidplaquesgrowmore
slowlyoverperiodsofweeks[55].Analysisoftheroleofbrain
inﬂammation in AD pathogeny has also been clariﬁed by
in vivo multiphoton imaging. For instance, the relationship
between plaques (labeled with Methoxy-X04) and activated
microglia (overexpressing GFP through an Iba-1 promoter)
has recently been described in APPxPS1 transgenics [56].
In a smart-engineered model (GFP inserted in the CX3CR1
chemokine receptor of the 5xTg AD model, which also
overexpressed Thy1-driven YFP), Fuhrman and colleagues
were able to describe the live dialogue between microglia
and neurons in the presence of AD lesions [57]. Finally,
in vivo multiphoton microscopy studies have also allowed
investigating thelocaltoxicity ofAβ deposits on surrounding
synapses and on neuritic processes. In direct support to the
amyloid cascade hypothesis, Meyer-Luehmann et al. [54]
demonstrated that plaques create a local microenvironment
(a reservoir of bioactive molecules) that gradually promotes
pathological changes in neighboring neurites within days.
Koﬃe et al. [58] underlined that Aβ oligomers, the so-called
“modern culprits” of AD, might be crucial players in these
synaptic/neuritic alterations; in APPxPS1 mice they labeled
plaques with Methoxy-XO4 and oligomers by infusing the
antioligomers NAB61 antibody conjugated to a ﬂuorescent
dyeonthecortexafterduraopening.Theywereabletodetect
in vivo a hallo of oligomers surrounding senile plaques; sub-
sequent histological analysis underlined that this peripheral
hallo was associated with a severe synaptotoxic eﬀect (loss
of PSD75 immunoreactivity). AD-related neuritic anomalies
detected byin vivo multiphoton microscopy might alsoserve
to evaluate the impact of new therapies. For instance, it
has been demonstrated that antioxidant treatments have a
rescuing action on neuritic dystrophies (abnormal neurite
curvature of ﬂuorescently labeled neurons) while not reduc-
ing Aβ plaque size [59]. On the contrary, the same research
group provided data showing that treatment with one γ-
secretase inhibitor (LY-411575) does not aﬀect the neuritic
defects of APPxPS1 transgenics [60].
3.2.2. PET Imaging of Amyloid Plaques. Although in vivo
multiphoton microscopy provided very interesting results
on the physiopathogeny of AD, the method cannot be
easily translated to patients. In humans, the best-established
method to detect amyloid plaques relies on the use of
the PiB radioligand. Although this compound was initially
evaluated in transgenic mouse models of AD [61]t od e t e c t
amyloid lesions by multiphoton imaging, it did not lead
to conclusive results when used to detect amyloid plaquesInternational Journal of Alzheimer’s Disease 5
by PET in APPxPS1 transgenic mice [62, 63]. Also, it has
been evidenced that 18F-FDDNP, a good radioligand for
amyloid plaques and tangles in humans, does not show good
retention in the brain of Tg2576 mice [64]. Using ultrahigh
speciﬁc-activity PiB (200GBq/mole; injection of the tracer
immediately after synthesis), Maeda and collaborators were
nevertheless able to show increased retention of the ligand
in APP transgenics. It is hence possible that paucity of high-
aﬃnity PiB binding sites in APP(xPS1) transgenic mice is
the explanation for previous imaging failures. It might also
be possible that the density of the high-aﬃnity PiB binding
sites varies from one transgenic line to the other (Maeda
and collaborators used the APP23 line while previous works
of Klunk and Tomaya were performed in Tg2576 APP
mice and in APPxPS1 transgenics derived from the Tg2576
model). Interestingly, Rosen et al. recently demonstrated
that PiB-binding is also reduced in aged rhesus macaques,
chimpanzees, and squirrel monkeys despite the fact that
the nonhuman primates they evaluated displayed heavy
amyloid burden [65]. It can be tentatively concluded that
PiB is an eﬃcient probe only for human-speciﬁc molecular
components of Aβ deposits. Despite diﬀerences between
humans and animals, the development of new radioligands
for AD brain lesions still strongly relies on preclinical tests
in APP(xPS1) transgenic mice. For example, the recently-
developed AV-45 ligand, which is expected to become a good
substitute to PiB in the coming years, has ﬁrst been tested in
transgenic mice [66].
3.2.3. MR Imaging of Amyloid Plaques. Direct noninvasive in
vivo imaging of plaques in APP(xPS1) transgenic mice is a
very stimulating research area and the MRI-based detection
of amyloid deposits is actively pursued as an alternative
technique to PET imaging in preclinical research. Numerous
studies performed in APP(xPS1) transgenic mice underlined
that discrete aggregated Aβ deposits locally modify MR
contrasts. These contrast anomalies can be detected in
postmortem conditions (extracted brains) that favor the
acquisition of high-resolution images [67–70] but they can
also be detected in vivo in anaesthetized mice [71–73]. One
mechanism that may explain the MRI spontaneous contrast
of plaques is the accumulation of iron in amyloid deposits
that locally alters the relaxation time of tissues [41, 74, 75].
T h er e c e n tw o r ko fM e a d o w c r o f ta n dc o l l a b o r a t o r s[ 76]
emphasized that both the high iron concentrations and the
interaction of water with dense aggregated amyloid mass can
concomitantly modify transverse relaxation rates but that
these two mechanisms might be diﬀerentially involved in
h u m a nv e r s u si nm o u s eb r a i nt i s s u e s .
MR imaging of plaques in rodents can also be per-
formed using speciﬁc probes. For example, the amyloid-
binding styrylbenzenes derived from the Congo red dye and
complexed to 19F (ﬂuorine) can pass through the blood-
brain barrier (BBB). One publication suggested that these
derivates can allow detection of Aβ deposits in living Tg2576
mice [77]. However, these results have not been replicated.
Aβ conjugated to gadolinium or monocrystalline iron
oxide nanoparticles (MIONs) are more robust methods for
amyloid plaque visualization. When administered periph-
erally (intravenous or intracarotid injection), the peptide-
contrast agent complexes have some tropism for amyloid
plaques thanks to the binding aﬃnity of Aβ peptides for
other Aβ peptides. However, brain penetration of the conju-
gates often requires the opening of the BBB (using mannitol)
or the complexion with polyamines (e.g., putrescin). These
vectorized contrast agents can be used “in vivo” to detect
amyloid plaques of AD transgenics [78, 79]a n de v e nt o
quantify amyloid load on a voxel-based analysis [80]. Recent
studies emphasized the use of small-sized antibodies to
build eﬃcient MRI probes against Aβ deposits. For instance,
Ramakrishnan and collaborators used polyamine-modiﬁed
Fab fragments complexed to gadolinium to perform ex
vivo amyloid plaque visualization by MRI in APPxPS1
mice [81]. Also, the group of Beka Solomon engineered
anti-Aβ ScFv antibodies by phage display, mainly with a
(immuno)therapeutical aim [82]. Interestingly, these small
antibodies, when infused intranasally, have the capacity to
penetrate into the brain and to reach the amyloid plaques,
not only at the injection loci (olfactory bulbs) but also at
longdistancesfromthenose,forinstance,inthehippocampi
[83]. It might hence be predicted that complexing these
phage-ScFv with an MRI contrast agent would allow in vivo
plaque detection. Also, the small homodimeric antibodies
of camelidae have been shown to be able to cross the BBB
after intracarotid infusion and to reach their targets in brain
parenchyma [84]. Some of these antibodies, much smaller
than the classical IgGs, have been speciﬁcally produced to
recognize Aβ epitopes [85, 86]a n dm i g h tb ev a l u a b l et o o l s
to initiate new strategies for in vivo plaque detection.
The MRI-based methods implemented in rodents could
ﬁnd a ﬁrst application in drug development as they oﬀer
a solution to monitor online the disease-modiﬁer eﬀects of
treatment in animal models of AD. Up to now, it has been
diﬃcult to evaluate the translation from these preclinical
data obtained in mice to valid MRI protocols utilizable
in AD patients. However, the rising development of high-
ﬁeld MRI for clinical and research uses might accelerate the
implementation of such noninvasive methods. Preliminary
studies hence suggest that amyloid plaques will soon be
detectable by MRI in humans [87, 88].
3.2.4. Other Imaging Approaches to Detect Amyloid Plaques.
Alternative methods for plaque imaging are under scruti-
nization in APP(xPS1) mice (e.g., Near InfraRed Fluores-
cence (NIRF) in vivo imaging of new compounds that bind
to plaques [89]o rD i ﬀraction Enhanced Imaging (DEI), a
phase contrast X-ray imaging technique that provides high
soft tissue contrast which allows Aβ plaque detection [90]).
These methods might also ﬁnd applications as preclinical
tools to screen the eﬀects of interventional therapies.
3.2.5. Relevance of Amyloid Plaque Detection. To conclude
on amyloid plaque imaging, it is important to remind that
while research eﬀorts have contributed to implement various
imaging techniques for the in vivo detection of amyloid
plaques in animal models, the exact status of these lesions as6 International Journal of Alzheimer’s Disease
core biomarkers of AD is still obscure and largely discussed.
It has been known for decades that Aβ accumulation can
be observed in nondemented human individuals and this
ﬁnding has recently been conﬁrmed by PiB-PET scans that
identiﬁed a subset of intellectually normal persons with a
high PiB ﬁxation indicating severe Aβ accumulation [17]. In
addition there is, today, no conclusive evidence to support
the hypothesis that reducing amyloid load by stimulating
plaque clearance has any clinical eﬀects in AD patients
[91]. Hence, the relevance of imaging plaques as primary
readouts for disease detection/progression as well as for the
evaluation of disease-modiﬁer therapies is challenged if not
questionable. This urges the need for (1) better reﬁning the
status of amyloid plaques as in vivo gold standard markers of
the disease, (2) stimulating new preclinical research eﬀorts
towards alternative biomarkers of AD.
3.3. Imaging of AD-Related Alterations of Brain Microstruc-
ture. Diﬀerent imaging parameters are altered in animals
developing cerebral amyloidosis but not necessarily as
a direct consequence of Aβ accumulation. For example,
anomalies of water diﬀu s i o nd e t e c t e db yi nv i v oM R Ih a v e
been described in AD transgenics accumulating amyloid
plaques [92–94] (see however [95]). The exact origin of
these diﬀusion defects is still uncertain (highly hydrophobic
deposits might cause constraints on water diﬀusion but
these defects might also come from loss or alterations of
the white matter). MR spectroscopy shows a decrease of N-
acetylaspartate (NAA) in the brains of APPxPS1 transgenics
[96]. NAA is considered to be a good marker of neuronal
viability; its decrease in APP(xPS1) mice might be caused
by the intraparenchymal accumulation of Aβ; some reports
indicatedindeedanegativecorrelationbetweenamyloidload
and NAA levels [97]. Although of interest, these methods
have not been used to followup disease progression in AD
preclinical models, maybe because the tracked markers are
not speciﬁc to AD condition and can be detected only in
the oldest animals. It is uncertain whether therapeutical




Besides directly imaging the microscopic and macroscopic
lesions of AD, it is also possible, even in animal models, to
follow the evolution of the pathological process through the
brainfunctionaldisorganizationsitpromotes(e.g.,perfusion
and neuronal activity impairments).
4.1. Vascular-Perfusion Anomalies. Since the initial obser-
vation of the occurrence of cerebral amyloid angiopathy
in AD patients, it has been well established that vascular
abnormalities are a major phenotype of the disease. Using
dedicated postmortem morphological analysis (e.g., corro-
sion casts) similar vascular impairments have been described
in AD transgenics under the form of eliminated/truncated
brain vessels or dysmorphic vascular architecture [98, 99].
Importantly, such drastic changes in the morphology of
brain vessels can also be visualized using in vivo magnetic
resonance angiography (MRA) that allows the detailed
detection of the vascular arborization in the brain. MRA
has been successfully applied to APP [98] and APPxPS1
[100] mice that both demonstrate abnormal arterial voids.
These methods are interesting tools to measure the preven-
tive/curative eﬀects of vascular-oriented therapies although
the relationship between the incidence of vessels anomalies
and Aβ brain deposition remains to be clariﬁed.
In parallel, the cerebral blood volume (CBV) of AD
transgenics has been observed to be reduced (for recent
illustration in a triple APPxPS1xtau line, see [101]). Shrink-
ing of the cerebrovascular space in rodents can be esti-
mated in vivo using MR detection of susceptibility contrast
agents such as gadolinium administered intraperitoneally
[102] or monocrystalline iron oxide nanoparticles injected
intravenously [103]. Restoration of normal CBV maps in
AD transgenics has been demonstrated across therapeutic
assays (e.g., long-term treatment with nonsteroidal anti-
inﬂammatory drugs in Tg J20 mice [102]).
As a more functional consequence of vascular impair-
ments in AD transgenics, blood perfusion is also decreased
in diﬀerent mouse models. This perfusion decrease can be
assessed using standard autoradiographic methods [104], by
laser Doppler [105], and by in vivo MRI (e.g., by means
of spin-labeling techniques). For instance, MRI detection of
perfusion impairments has been performed in APPxPS1-Ki
mice [106] and in PS2APP mice [107].
4.2. Metabolic, Cellular, and Network Dysfunction. Record-
ings of cortical hypometabolism as measured by PET
imaging and brain hypoactivities assessed by functional MRI
are hallmarks classically described in AD patients. Similar
anomalies can be observed in mouse models of AD. Thanks
to their high spatial resolution, autoradiographic methods
(e.g., of ﬂuorodeoxyglucose-FDG or of 2-deoxy-D-glucose)
have been applied to map brain metabolic activities in
PDAPP mice [108, 109] and in APPxPS1 transgenics [110].
In these transgenic mice, hypometabolism was constantly
evidenced in the association cortex (e.g., posterior cingulate
cortex), evocative of ﬁndings obtained in AD patients. How-
ever, the relationship between these functional anomalies
and amyloid burden is still questioned [109].
In vivo metabolic imaging in mice undergoes rapid
development but it is technically challenging because PET
imaging in rodents is limited by its low resolution, the
cost of the ligands, and access to micro-PET devices. Also,
recent data indicated no diﬀerences in FDG-PET between
AD transgenics (Tg2576 mice) and control animals [64].
Alternative ways to visualize brain activity in living mice
areavailable.Therecentdevelopmentofinvivomultiphoton
calcium imaging techniques applied to AD mouse models
[111–113] has provided us with remarkable new ﬁndings
on the disease physiopathogeny but their use for therapeutic
preclinical development is doubtful. Manganese-Enhanced
MRI (MEMRI) is a better-established method to follow
brain activity in rodents. It allows the in vivo detection ofInternational Journal of Alzheimer’s Disease 7
active neuronal populations in rats, mice, and in nonhuman
primates [114]. Manganese is an analog of calcium and
afterperipheralorstereotaxicadministrationitcanpenetrate
into brain neurons via voltage-dependent Ca2+ channels.
Paramagnetic properties of manganese allow its direct
visualization by MRI. A raise in manganese concentrations
has been described in selected brain regions following
interoceptive/exteroceptive stimulations [115, 116]. We are
not currently aware of any reports that have applied this
pioneering method to map brain activities in APP or
APPxPS1 mice. Kimura and collaborators conversely used
MEMRI analysis in mice overexpressing tau and accumu-
lating hyperphosphorylated tau in their brains [117]. The
authors reported clear cortical hypoactivation in the tau
mice, at the level of the postrhinal cortex (homologous to
the parahippocampal area of primates, including humans)
and in tight association with the occurrence of visuospatial
cognitive deﬁcits. In addition to being a good marker of
activated neurons, manganese is also transported in axons
via microtubules. It can therefore be used as an in vivo
transsynaptic tracer to label brain networks in situ. Delays
in manganese transport, assessing malfunction of brain
connectivity, presumably as a response to synaptic/neuritic
underlying pathologies, have recently been evidenced in
APP and APPxPS1 transgenic mice [118, 119]. Interestingly,
the analysis of transneuronal manganese transport can be
used to screen the eﬀects of therapies against AD (e.g.,
memantine[120]).Althoughassociatedwithknownputative
toxic eﬀects [114, 121], MEMRI might rapidly become a
prominent method for the analysis of brain dysfunction
in AD transgenic mice and of functional recovery after
therapeutical intervention.
5. Conclusions
AD biomarkers have the opportunity to be developed, tested
and validated in mouse models of the disease. In many cases,
mice have allowed to produce the ﬁrst proof of concept
for biomarkers that have been then translated to humans.
This is the case of radioligands that now allow the detection
of amyloid plaques by PET in patients. MR biomarkers of
amyloid plaques underwent a similar development pipeline
(ﬁrst tested in mice, then applied to humans). In the near
future, one can predict that transgenic models will play a
decisive role in the investigation of new biomarkers of AD
pathology, such as, for example, markers of Tau pathology
that are critically missing today.
Interestingly, major brain changes detected in AD
patients (e.g., cerebral atrophy or reduced brain metabolism
detected by FDG-PET) are not always replicated in animals.
Such discrepancies can be explained by technical considera-
tions but are also attributable to the intrinsic characteristics
of the model and to its inability to mimic all aspects of
the human pathology. On the other hand, a large range
of biomarkers detecting AD brain alterations in humans is
detectable in a similar way in transgenic mice. For instance,
biomarkers of amyloid plaques, perfusion, and cerebral
blood volume are all valid both in AD patients and in
mouse models of the disease. These markers are critical
to followup disease progression, to monitor the eﬀects of
treatments during preclinical studies, and to predict possible
therapeutic eﬀects in humans. They can thus be considered
as good translational biomarkers of AD pathology. Finally,
some markers and their associated methodologies have been
implemented in animals and will probably be restricted to
preclinical studies. These markers could be of importance
to reﬁne our understanding of the physiopathogeny of the
disease or, alternatively, to detect the eﬀects of new therapies
initiated in animal models. This is particularly true for
invasive approaches such as bi-photon imaging of amyloid
plaques or for methods relying on potentially toxic contrast
agents such as manganese-enhanced MRI.
Toconclude,transgenicmousemodelsofADcanbeused
as tools to identify and validate new translational biomarkers
of AD pathology. In parallel, the markers identiﬁed in these
models might have a ﬁeld of application restricted to the
sole preclinical research but still with an interest for both
fundamental and therapeutical investigations.
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